Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-04-28 AGM Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于召开2024年年度股东会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a detailed notice and agenda for the 2024 Annual General Meeting (AGM) of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting date, voting methods, attendees, and the various proposals to be discussed and voted on at the AGM, such as the 2024 annual reports, audit reports, financial budgets, remuneration plans, and financing authorizations. The document does not contain the actual reports or financial statements but rather announces the meeting and the items to be considered. It also includes an authorization proxy form for shareholders to vote. The document length is 6443 characters, which is consistent with a detailed AGM notice rather than a full annual report or audit report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-28 Chinese
内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a registered accounting firm (Ernst & Young) and addresses the effectiveness of internal controls over financial reporting as of December 31, 2024. The content includes auditor responsibilities, management responsibilities, inherent limitations of internal control, and an audit opinion on the effectiveness of internal controls. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. The length is 1469 characters, indicating it is a concise audit report rather than a full annual report or other extensive document. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-04-28 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司2024年度募集资金存放与实际使用情况的核查意见
Regulatory Filings
2025-04-28 Chinese
关于三价HPV疫苗上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a marketing authorization application for a trivalent HPV vaccine by the National Medical Products Administration (CDE) in China. It discusses the vaccine's clinical trial results, regulatory status, potential impact on the company, and associated risks. The document is relatively short (1262 characters) and serves as a formal notification of a regulatory milestone rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed investor information. It is not an earnings release, annual report, or any form of financial supplement. It is also not a proxy, voting result, or board change announcement. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about the company's product approval process and related disclosures.
2025-04-22 Chinese
高级管理人员任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management officer, specifically the Chief Marketing Officer, including details about the appointment process, qualifications, and impact on the company. It references the board meeting resolutions and complies with relevant laws and company bylaws. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-04-09 Chinese
第五届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the eighth meeting of the fifth supervisory board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting's time, place, attendance, and the approval of a proposal regarding a subsidiary's bank credit application and related guarantees. The document does not contain financial statements or detailed financial data but is an official announcement of a board meeting decision. It is not an annual report, audit report, earnings release, or any other financial report. It is also not a regulatory filing or certification. The content fits best under Board/Management Information (MANG) as it relates to board/supervisory meeting resolutions and decisions.
2025-04-09 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.